Kalvista Pharmaceuticals (NASDAQ:KALV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The firm currently has a $19.00 price objective on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 22.19% from the company’s current price.

According to Zacks, “KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States. “

KALV has been the topic of several other reports. ValuEngine upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Roth Capital assumed coverage on shares of Kalvista Pharmaceuticals in a research report on Tuesday, July 10th. They set a “buy” rating and a $20.00 price objective on the stock. Four analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $22.00.

Shares of Kalvista Pharmaceuticals stock opened at $15.55 on Wednesday. The firm has a market cap of $203.28 million, a PE ratio of -10.16 and a beta of 3.07. Kalvista Pharmaceuticals has a 1-year low of $6.65 and a 1-year high of $18.90.

Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Tuesday, July 31st. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.29. The business had revenue of $4.84 million for the quarter. Kalvista Pharmaceuticals had a negative net margin of 188.29% and a negative return on equity of 55.65%. equities research analysts forecast that Kalvista Pharmaceuticals will post -0.93 earnings per share for the current fiscal year.

In other news, Director Albert Cha acquired 1,058,824 shares of the firm’s stock in a transaction dated Monday, September 10th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $18,000,008.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 49.10% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. DRW Securities LLC raised its position in shares of Kalvista Pharmaceuticals by 37.3% during the 2nd quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock valued at $167,000 after purchasing an additional 5,600 shares during the period. BlackRock Inc. increased its holdings in Kalvista Pharmaceuticals by 203.8% in the 2nd quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 10,871 shares during the last quarter. Spark Investment Management LLC bought a new stake in Kalvista Pharmaceuticals in the 2nd quarter valued at $108,000. Stanley Laman Group Ltd. increased its holdings in Kalvista Pharmaceuticals by 48.3% in the 2nd quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock valued at $545,000 after acquiring an additional 21,861 shares during the last quarter. Finally, Eventide Asset Management LLC increased its holdings in Kalvista Pharmaceuticals by 26.9% in the 1st quarter. Eventide Asset Management LLC now owns 900,000 shares of the specialty pharmaceutical company’s stock valued at $8,532,000 after acquiring an additional 191,000 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Read More: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on Kalvista Pharmaceuticals (KALV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.